Stock Events

Stock Events

LeonaBio 

$7.75
36
+$0.05+0.65% 18:35 Today

Statistics

Day High
7.92
Day Low
7.44
52W High
14.21
52W Low
3.53
Volume
12,912
Avg. Volume
36,657
Mkt Cap
73.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-2.28
-1.75
-1.22
-0.69
Expected EPS
-0.685
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-105.61MNet Income

Analyst Ratings

17.33Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen is a leading biotech company focusing on neurodegenerative diseases, directly competing with Athira Pharma's focus on Alzheimer's and other neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Athira Pharma in the neurodegenerative disease space.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals focuses on the development of drugs to treat central nervous system disorders, competing with Athira Pharma in the neurology and psychiatry treatment market.
AnaptysBio
ANAB
Mkt Cap1.67B
AnaptysBio is engaged in developing therapeutic antibodies for the treatment of neuroinflammatory diseases, positioning it as a competitor in the neurodegenerative disease market.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. specializes in the development of novel therapeutics for the treatment of Alzheimer's disease, Parkinson's, and other central nervous system diseases.
Prothena
PRTA
Mkt Cap478.97M
Prothena Corporation plc is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative diseases, including Alzheimer's.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics, Inc. is developing novel therapies for central nervous system (CNS) disorders, including cognitive disorders related to Alzheimer's disease.
Arbutus Biopharma
ABUS
Mkt Cap1B
Arbutus Biopharma Corporation is slightly less directly competitive but is involved in the development of therapies for viral diseases and associated neurodegenerative conditions.

About

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Show more...
CEO
Mark J. Litton
Employees
19
Country
United States
ISIN
US04746L2034
WKN
000A2QCFW

Listings

BOATS
BOATS
LONA.BOATS
F
DE
6AI.F
XNAS
US
LONA

0 Comments

Share your thoughts

FAQ

What is LeonaBio stock price today?▼
The current price of LONA is $7.75 USD — it has increased by +0.65% in the past 24 hours. Watch LeonaBio stock price performance more closely on the chart.
What is LeonaBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange LeonaBio stocks are traded under the ticker LONA.
What is LeonaBio market cap?▼
Today LeonaBio has the market capitalization of 73.02M
When is the next LeonaBio earnings date?▼
LeonaBio is going to release the next earnings report on November 05, 2026.
What were LeonaBio earnings last quarter?▼
LONA earnings for the last quarter are -0.8 USD per share, whereas the estimation was -1.39 USD resulting in a +42.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is LeonaBio revenue for the last year?▼
LeonaBio revenue for the last year amounts to 0 USD.
What is LeonaBio net income for the last year?▼
LONA net income for the last year is -105.61M USD.
How many employees does LeonaBio have?▼
As of September 04, 2026, the company has 19 employees.
In which sector is LeonaBio located?▼
LeonaBio operates in the Health & Wellness sector.
When did LeonaBio complete a stock split?▼
The last stock split for LeonaBio was on September 18, 2025 with a ratio of 1:10.
Where is LeonaBio headquartered?▼
LeonaBio is headquartered in BOTHELL, United States.